Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy

Primary Objectives:

Objective 1 (Primary Objective): to examine preliminary baseline and serial electrophysiological markers associated with the onset and development of CIPN by tracking brain activity and CIPN symptoms throughout chemotherapy treatment.

Secondary Objectives:

Objective 2 (Secondary Objective): To preliminarily evaluate whether a clBCI program can regulate changes in EEG that are associated with CIPN while participants are undergoing chemotherapy.

Exploratory Objective: Explore whether there are associations between change in brain function and subjective report of CIPN.

Inclusion criteria

Objective 1 Inclusion criteria

• Participants must have the ability to understand and read English, sign a written informed consent, and be willing to follow protocol requirements.
• ECOG Performance Status of 0-2;
• Willing to come to MD Anderson for the imaging sessions.
• Are 18 years of age or above.
• Have a diagnosis of breast cancer.
• will receive chemotherapy including doxorubicin, cyclophosphamide, docetaxel, or paclitaxel;

Objective 2 Inclusion criteria:

• Inclusion criteria: Identical to Objective 1 and are willing to participate in the therapy sessions at their homes.

Exclusion criteria

Objective 1 Exclusion criteria:

• Participants who are taking any antipsychotic medications.
• With active CNS disease, such as clinically evident metastases or leptomeningeal disease, dementia, or encephalopathy.
• Have ever been diagnosed with bipolar disorder or schizophrenia.
• Known, previously diagnosed peripheral neuropathy from any causes and
• A history of head injury or who have known seizure activity.

Objective 2 Exclusion criteria

• Same exclusion criteria as in Objective1. Medication usage will be tracked for patients in all groups. Once prescribed, participants must remain on a stable course of medications throughout the course of chemotherapy.